-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

Benzinga·10/21/2026 14:33:50
Listen to the news
B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.